Detection of urinary survivin using a magnetic particles‑based chemiluminescence immunoassay for the preliminary diagnosis of bladder cancer and renal cell carcinoma combined with LAPTM4B

Yang,Yang; Xu,Jianjun; Zhang,Qingyun

doi:10.3892/ol.2018.8317

Detection of urinary survivin using a magnetic particles‑based chemiluminescence immunoassay for the preliminary diagnosis of bladder cancer and renal cell carcinoma combined with LAPTM4B

Authors:
- Yang Yang
- Jianjun Xu
- Qingyun Zhang
View Affiliations

Affiliations: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Clinical Laboratory, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China
Published online on: March 22, 2018 https://doi.org/10.3892/ol.2018.8317
Pages: 7923-7933
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to establish a simple step magnetic particles (MPs) based chemiluminescence enzyme immunoassay (CLEIA) for the detection of urinary survivin, and to investigate the diagnostic value of urinary survivin and lysosome‑associated protein transmembrane‑4β (LAPTM4B) in bladder cancer (BC) and renal cell carcinoma (RCC). The MPs‑based CLEIA was developed on the basis of a double antibodies sandwich immunoreaction and luminol‑H2O2 chemiluminescence system. The parameters of the method were optimized and evaluated. Urine samples were obtained from 200 BC patients, 81 RCC patients and 114 healthy individuals, and the MPs‑based CLEIA method was employed to detect their urinary survivin. At the same time, the urinary LAPTM4B levels of the BC patients, RCC patients and the healthy controls were measured. The diagnostic efficiency of urinary survivin and LAPTM4B in BC and RCC was evaluated separately and jointly. A one‑step MPs‑based CLEIA for the detection of urinary survivin with good accuracy and precision was established. The signals were dependent on survivin concentrations in the range, 0 to 200 ng/ml, and the detection limit was 0.949 ng/ml. The areas under the receiver operating characteristic curves (AUC) were 0.771 in BC and 0.763 in RCC for urinary survivin. Urinary survivin was correlated with the tumor stage (P=0.002), lymph node metastasis (P=0.017), distant metastasis (P=0.005) and tumor size (P=0.02) of BC; however, no association with the clinicopathological parameters in RCC was observed. The AUCs for urinary LAPTM4B were 0.738 in BC and 0.704 in RCC, respectively. The AUCs for them combined were 0.842 in BC and 0.920 in RCC. The MPs‑based CLEIA was performed well in the detection of urinary survivin. Urinary survivin and LAPTM4B could serve as potential biomarkers for the preliminary diagnosis of BC and RCC, and in combination they a achieved a greater diagnostic performance.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
3	Fiedler GM, Baumann S, Leichtle A, Oltmann A, Kase J, Thiery J and Ceglarek U: Standardized peptidome profiling of human urine by magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem. 53:421–428. 2007. View Article : Google Scholar : PubMed/NCBI
4	Saito M, Kimoto M, Araki T, Shimada Y, Fujii R, Oofusa K, Hide M, Usui T and Yoshizato K: Proteome analysis of gelatin-bound urinary proteins from patients with bladder cancers. Eur Urol. 48:865–871. 2005. View Article : Google Scholar : PubMed/NCBI
5	Chou R, Gore JL, Buckley D, Fu R, Gustafson K, Griffin JC, Grusing S and Selph S: Urinary biomarkers for diagnosis of bladder cancer: A systematic review and meta-analysis. Ann Intern Med. 163:922–931. 2015. View Article : Google Scholar : PubMed/NCBI
6	Guo A, Wang X, Gao L, Shi J, Sun C and Wan Z: Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: A meta-analysis. Can Urol Assoc J. 8:E347–E352. 2014. View Article : Google Scholar : PubMed/NCBI
7	Pichler R, Tulchiner G, Fritz J, Schaefer G, Horninger W and Heidegger I: Urinary UBC rapid and NMP22 test for bladder cancer surveillance in comparison to urinary cytology: Results from a prospective single-center study. Int J Med Sci. 14:811–819. 2017. View Article : Google Scholar : PubMed/NCBI
8	Papale M, Vocino G, Lucarelli G, Rutigliano M, Gigante M, Rocchetti MT, Pesce F, Sanguedolce F, Bufo P, Battaglia M, et al: Urinary RKIP/p-RKIP is a potential diagnostic and prognostic marker of clear cell renal cell carcinoma. Oncotarget. 8:40412–40424. 2017. View Article : Google Scholar : PubMed/NCBI
9	Altieri DC: Survivin-The inconvenient IAP. Semin Cell Dev Biol. 39:91–96. 2015. View Article : Google Scholar : PubMed/NCBI
10	El-Hakim Abd TF, El-Shafie MK, Abdou AG, Azmy RM, El-Naidany SS and El-Din Badr MO: Value of urinary survivin as a diagnostic marker in bladder cancer. Anal Quant Cytopathol Histpathol. 36:121–127. 2014.PubMed/NCBI
11	Meng Y, Wang L, Chen D, Chang Y, Zhang M, Xu JJ, Zhou R and Zhang QY: LAPTM4B: An oncogene in various solid tumors and its functions. Oncogene. 35:6359–6365. 2016. View Article : Google Scholar : PubMed/NCBI
12	Chang Y, Xu J and Zhang Q: Microplate magnetic chemiluminescence immunoassay for detecting urinary survivin in bladder cancer. Oncol Lett. 14:4043–4052. 2017. View Article : Google Scholar : PubMed/NCBI
13	Wang Y, Zhang QY and Wang YM: Cloning of survivin gene and preparation its monoclonal antibodies as well as checking survivin expression in liver carcinoma cells. Chin J Lab Med. 29:258–262. 2006.(In Chinese).
14	Chatziharalambous D, Lygirou V, Latosinska A, Stravodimos K, Vlahou A, Jankowski V and Zoidakis J: Analytical performance of ELISA assays in urine: One more bottleneck towards biomarker validation and clinical implementation. PLoS One. 11:e01494712016. View Article : Google Scholar : PubMed/NCBI
15	Thway T and Salimi-Moosavi H: Evaluating the impact of matrix effects on biomarker assay sensitivity. Bioanalysis. 6:1081–1091. 2014. View Article : Google Scholar : PubMed/NCBI
16	Wang X, Lin JM and Ying X: Evaluation of carbohydrate antigen 50 in human serum using magnetic particle-based chemiluminescence enzyme immunoassay. Anal Chim Acta. 598:261–267. 2007. View Article : Google Scholar : PubMed/NCBI
17	Zhang Q, Wang X, Li Z and Lin JM: Evaluation of alpha-fetoprotein (AFP) in human serum by chemiluminescence enzyme immunoassay with magnetic particles and coated tubes as solid phases. Anal Chim Acta. 631:212–217. 2009. View Article : Google Scholar : PubMed/NCBI
18	Wang X, Zhang QY, Li ZJ, Ying XT and Lin JM: Development of high-performance magnetic chemiluminescence enzyme immunoassay for alpha-fetoprotein (AFP) in human serum. Clin Chim Acta. 393:90–94. 2008. View Article : Google Scholar : PubMed/NCBI
19	Horstmann M, Bontrup H, Hennenlotter J, Taeger D, Weber A, Pesch B, Feil G, Patschan O, Johnen G, Stenzl A and Brüning T: Clinical experience with survivin as a biomarker for urothelial bladder cancer. World J Urol. 28:399–404. 2010. View Article : Google Scholar : PubMed/NCBI
20	Chen HA, Su CM, Hsieh HY, Tung CL, Hsu CD, Wang YH and Shen CH: Clinical significance of survivin expression in patients with urothelial carcinoma. Dis Markers. 2014:5749852014. View Article : Google Scholar : PubMed/NCBI
21	Gogalic S, Sauer U, Doppler S and Preininger C: Bladder cancer biomarker array to detect aberrant levels of proteins in urine. Analyst. 140:724–735. 2015. View Article : Google Scholar : PubMed/NCBI
22	Schmidt J, Propping C, Siow WY, Lohse-Fischer A, Toma M, Baldauf-Twelker A, Hakenberg OW, Wirth MP and Fuessel S: Diagnostic and prognostic value of bladder cancer-related transcript markers in urine. J Cancer Res Clin Oncol. 142:401–414. 2016. View Article : Google Scholar : PubMed/NCBI
23	Sah NK and Seniya C: Survivin splice variants and their diagnostic significance. Tumour Biol. 36:6623–6631. 2015. View Article : Google Scholar : PubMed/NCBI
24	Zamparese R, Pannone G, Santoro A, Lo Muzio L, Corsi F, Pedicillo MC, Scillitani EL, Tortorella S, Staibano S, Piscuoglio S, et al: Survivin expression in renal cell carcinoma. Cancer Invest. 26:929–935. 2008. View Article : Google Scholar : PubMed/NCBI
25	Byun SS, Yeo WG, Lee SE and Lee E: Expression of survivin in renal cell carcinomas: Association with pathologic features and clinical outcome. Urology. 69:34–37. 2007. View Article : Google Scholar : PubMed/NCBI
26	Lei Y, Geng Z, Guo-Jun W, He W and Jian-Lin Y: Prognostic significance of survivin expression in renal cell cancer and its correlation with radioresistance. Mol Cell Biochem. 344:23–31. 2010. View Article : Google Scholar : PubMed/NCBI
27	Shi ZG, Li SQ, Li ZJ, Zhu XJ, Xu P and Liu G: Expression of vimentin and survivin in clear cell renal cell carcinoma and correlation with p53. Clin Transl Oncol. 17:65–73. 2015. View Article : Google Scholar : PubMed/NCBI
28	Adachi J, Kumar C, Zhang Y, Olsen JV and Mann M: The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol. 7:R802006. View Article : Google Scholar : PubMed/NCBI
29	Baytekin F, Tuna B, Mungan U, Aslan G and Yorukoglu K: Significance of P-glycoprotein, p53, and survivin expression in renal cell carcinoma. Urol Oncol. 29:502–507. 2011. View Article : Google Scholar : PubMed/NCBI
30	Yang Y, Yang H, McNutt MA, Xiong F, Nie X, Li L and Zhou R: LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma. Oncol Rep. 20:1077–1083. 2008.PubMed/NCBI
31	Zhou L, He XD, Cui QC, Zhou WX, Qu Q, Zhou RL, Rui JA and Yu JC: Expression of LAPTM4B-35: A novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett. 264:209–217. 2008. View Article : Google Scholar : PubMed/NCBI
32	Kang Y, Yin M, Jiang W, Zhang H, Xia B, Xue Y and Huang Y: Overexpression of LAPTM4B-35 is associated with poor prognosis in colorectal carcinoma. Am J Surg. 204:677–683. 2012. View Article : Google Scholar : PubMed/NCBI
33	Yang H, Xiong FX, Lin M, Yang Y, Nie X and Zhou RL: LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol. 136:275–281. 2010. View Article : Google Scholar : PubMed/NCBI
34	Li S, Wang L, Meng Y, Chang Y, Xu J and Zhang Q: Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients. Oncotarget. 8:41282–41293. 2017.PubMed/NCBI
35	Zerefos PG and Vlahou A: Urine sample preparation and protein profiling by two-dimensional electrophoresis and matrix-assisted laser desorption ionization time of flight mass spectroscopy. Methods Mol Biol. 428:141–157. 2008. View Article : Google Scholar : PubMed/NCBI
36	Li L, Shan Y, Yang H, Zhang S, Lin M, Zhu P, Chen XY, Yi J, McNutt MA, Shao GZ and Zhou RL: Upregulation of LAPTM4B-35 promotes malignant transformation and tumorigenesis in L02 human liver cell line. Anat Rec (Hoboken). 294:1135–1142. 2011. View Article : Google Scholar : PubMed/NCBI
37	Sjödahl G, Lövgren K, Lauss M, Patschan O, Gudjonsson S, Chebil G, Aine M, Eriksson P, Månsson W, Lindgren D, et al: Toward a molecular pathologic classification of urothelial carcinoma. Am J Pathol. 183:681–691. 2013. View Article : Google Scholar : PubMed/NCBI
38	Eriksson P, Aine M, Veerla S, Liedberg F, Sjödahl G and Höglund M: Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems. BMC Med Genomics. 8:252015. View Article : Google Scholar : PubMed/NCBI
39	Li Z, Li X, Li C, Su Y, Fang W, Zhong C, Ji W, Zhang Q and Su C: Transcription factor OCT4 promotes cell cycle progression by regulating CCND1 expression in esophageal carcinoma. Cancer Lett. 354:77–86. 2014. View Article : Google Scholar : PubMed/NCBI
40	Cao L, Li C, Shen S, Yan Y, Ji W, Wang J, Qian H, Jiang X, Li Z, Wu M, et al: OCT4 increases BIRC5 and CCND1 expression and promotes cancer progression in hepatocellular carcinoma. BMC Cancer. 13:822013. View Article : Google Scholar : PubMed/NCBI
41	Elmegeed GA, Yahya SM, Abd-Elhalim MM, Mohamed MS, Mohareb RM and Elsayed GH: Evaluation of heterocyclic steroids and curcumin derivatives as anti-breast cancer agents: Studying the effect on apoptosis in MCF-7 breast cancer cells. Steroids. 115:80–89. 2016. View Article : Google Scholar : PubMed/NCBI
42	Diaz A, Valera A, Carrera C, Hakim S, Aguilera P, García A, Palou J, Puig S, Malvehy J and Alos L: Pigmented spindle cell nevus: Clues for differentiating it from spindle cell malignant melanoma. A comprehensive survey including clinicopathologic, immunohistochemical, and FISH studies. Am J Surg Pathol. 35:1733–1742. 2011. View Article : Google Scholar : PubMed/NCBI
43	Sun L, Hu H, Peng L, Zhou Z, Zhao X, Pan J, Sun L, Yang Z and Ran Y: P-cadherin promotes liver metastasis and is associated with poor prognosis in colon cancer. Am J Pathol. 179:380–390. 2011. View Article : Google Scholar : PubMed/NCBI
44	Breyer J, Gierth M, Shalekenov S, Aziz A, Schäfer J, Burger M, Denzinger S, Hofstädter F, Giedl C and Otto W: Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma. World J Urol. 34:709–716. 2016. View Article : Google Scholar : PubMed/NCBI
45	Rodriguez L, Villalobos X, Dakhel S, Padilla L, Hervas R, Hernández JL, Ciudad CJ and Noé V: Polypurine reverse Hoogsteen hairpins as a gene therapy tool against survivin in human prostate cancer PC3 cells in vitro and in vivo. Biochem Pharmacol. 86:1541–1554. 2013. View Article : Google Scholar : PubMed/NCBI
46	Jiang Y, Saavedra HI, Holloway MP, Leone G and Altura RA: Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem. 279:40511–40520. 2004. View Article : Google Scholar : PubMed/NCBI
47	Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, et al: Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 21:2613–2622. 2002. View Article : Google Scholar : PubMed/NCBI
48	Wang Q and Greene MI: EGFR enhances Survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway. Exp Mol Pathol. 79:100–107. 2005. View Article : Google Scholar : PubMed/NCBI
49	Tian M, Chen Y, Tian D, Qiao X, Ma Z and Li J: Beclin1 antagonizes LAPTM4B-mediated EGFR overactivation in gastric cancer cells. Gene. 626:48–53. 2017. View Article : Google Scholar : PubMed/NCBI
50	Tan X, Sun Y, Thapa N, Liao Y, Hedman AC and Anderson RA: LAPTM4B is a PtdIns(4,5)P2 effector that regulates EGFR signaling, lysosomal sorting, and degradation. EMBO J. 34:475–490. 2015. View Article : Google Scholar : PubMed/NCBI
51	Momeny M, Zarrinrad G, Moghaddaskho F, Poursheikhani A, Sankanian G, Zaghal A, Mirshahvaladi S, Esmaeili F, Eyvani H, Barghi F, et al: Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells. Sci Rep. 7:42042017. View Article : Google Scholar : PubMed/NCBI